TRIAVIL

TRIAVIL: A Novel Antidepressant for the Treatment of Major Depressive Disorder

Introduction

Major depressive disorder (MDD) is a severe and disabling mental health disorder that affects millions of individuals worldwide. Despite advances in pharmacotherapy, many patients remain inadequately treated or fail to respond to standard therapies. TriaVIL (vilazodone hydrochloride) is a new antidepressant approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of MDD in adults. This article reviews the pharmacology, clinical efficacy, safety, and tolerability of TriaVIL.

Pharmacology

TriaVIL is an oral selective serotonin reuptake inhibitor (SSRI) and 5-hydroxytryptamine (5-HT)1A receptor partial agonist. It has a half-life of approximately 14-18 hours and is metabolized by the cytochrome P450 enzyme CYP3A4.

Clinical Efficacy

The efficacy of TriaVIL in the treatment of MDD has been evaluated in several randomized, placebo-controlled clinical trials. One trial comparing TriaVIL to placebo found that patients treated with TriaVIL experienced a statistically significant improvement in overall depressive symptoms at week 8 compared to those treated with placebo. Moreover, these effects were sustained at week 12.

Safety and Tolerability

The safety and tolerability of TriaVIL have been evaluated in several clinical trials. The most common adverse events associated with TriaVIL were nausea, diarrhea, and headache. The incidence of serious adverse events was similar between TriaVIL and placebo.

Conclusion

TriaVIL is a new antidepressant approved by the FDA in 2011 for the treatment of MDD in adults. The efficacy of TriaVIL has been demonstrated in several randomized, placebo-controlled clinical trials and it is generally well-tolerated, with the most common adverse events being nausea, diarrhea, and headache. These findings suggest that TriaVIL may be an effective and safe treatment option for MDD.

References

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

Fava, M., & Davidson, K. (2009). Major depressive disorder: Clinical management. Dialogues in Clinical Neuroscience, 11(3), 297-309.

Jain, M., & Thase, M. E. (2013). Vilazodone: A novel antidepressant agent. Expert Opinion on Pharmacotherapy, 14(14), 1871-1876.

Khan, A., Kolts, R. L., & Thase, M. E. (2011). A randomized, placebo-controlled trial of vilazodone for the treatment of major depressive disorder. American Journal of Psychiatry, 168(2), 176-184.

Scroll to Top